Daniel Messroghli
Overview
Explore the profile of Daniel Messroghli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller M, Brand A, Mattig I, Spethmann S, Messroghli D, Hahn K, et al.
Circ Heart Fail
. 2025 Jan;
18(2):e012146.
PMID: 39866106
Background: Despite previous histopathologic evidence for its presence, the role of myocardial inflammation in the development and progression of cardiac transthyretin amyloidosis (ATTR-CA) remains insufficiently understood. Thus, this study sought...
2.
Muller M, Spethmann S, Messroghli D, Brand A, Mattig I, Hahn K, et al.
JACC Adv
. 2025 Jan;
4(2):101568.
PMID: 39826440
Background: Biomarker-based prognostic staging systems, including the National Amyloidosis Centre (NAC) and the Mayo staging systems, are widely-used but have only been validated for treatment-naive patients with cardiac transthyretin amyloidosis...
3.
Rolfs N, Huber C, Opgen-Rhein B, Altmann I, Anderheiden F, Hecht T, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457681
Risk assessment in pediatric myocarditis is challenging, particularly when left ventricular ejection fraction (LVEF) is preserved. This study aimed to evaluate LV myocardial deformation using speckle-tracking echocardiography (STE)-derived longitudinal +strain...
4.
Muller M, Latinova E, Brand A, Mattig I, Spethmann S, Messroghli D, et al.
J Am Heart Assoc
. 2024 Jul;
13(14):e033478.
PMID: 38958150
Background: Results from ATTR-ACT (Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy) indicate that tafamidis prolongs survival and reduces cardiovascular hospitalizations in cardiac transthyretin amyloidosis (ATTR-CA). However, real-world...
5.
Pernice H, Knorz A, Wetzel P, Herrmann C, Muratovic H, Rieber F, et al.
Sci Rep
. 2024 May;
14(1):10111.
PMID: 38698025
In contrast to inherited transthyretin amyloidosis (A-ATTRv), neuropathy is not a classic leading symptom of wild type transthyretin amyloidosis (A-ATTRwt). However, neurological symptoms are increasingly relevant in A-ATTRwt as well....
6.
Rolfs N, Huber C, Schwarzkopf E, Mentzer D, Keller-Stanislawski B, Opgen-Rhein B, et al.
Am Heart J
. 2023 Nov;
267:101-115.
PMID: 37956921
Background: Since the onset of widespread COVID-19 vaccination, increased incidence of COVID-19 vaccine-associated myocarditis (VA-myocarditis) has been noted, particularly in male adolescents. Methods: Patients <18 years with suspected myocarditis following...
7.
Mohan A, Prasad S, Schmitz-Peiffer F, Lange C, Lukas M, Koziolek E, et al.
Endocr Relat Cancer
. 2023 Nov;
31(1).
PMID: 37943630
The mechanistic target of rapamycin complex 1 (mTORC1) inhibitor everolimus is one of the few approved therapies for locally advanced and metastatic neuroendocrine tumours (NETs). However, after initial disease stabilisation,...
8.
Schoffl I, Holler S, Dittrich S, Pickardt T, Opgen-Rhein B, Boehne M, et al.
Front Sports Act Living
. 2023 Jul;
5:1197640.
PMID: 37435596
Background: Myocarditis represents one of the most common causes of Sudden Cardiac Death in children. Myocardial involvement during a viral infection is believed to be higher as a consequence of...
9.
Benini A, Bingel A, Neumann K, Edelmann F, Schonrath F, Pieske B, et al.
Open Heart
. 2022 Dec;
9(2).
PMID: 36543361
Aims: We investigated the incremental advantage in terms of N-terminal pro-B-type natriuretic peptide (NT-proBNP) reduction in patients affected by heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (S/V)...
10.
Fauvel C, Bonnet G, Mullens W, Giraldo C, Meznar A, Barasa A, et al.
Eur J Heart Fail
. 2022 Nov;
25(2):213-222.
PMID: 36404398
Aims: In symptomatic patients with heart failure and reduced ejection fraction (HFrEF), recent international guidelines recommend initiating four major therapeutic classes rather than sequential initiation. It remains unclear how this...